Janux Therapeutics
JANX
About: Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Employees: 103
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
46% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 54
34% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $15.1M
1.87% less ownership
Funds ownership: 112.47% [Q1] → 110.6% (-1.87%) [Q2]
4% less funds holding
Funds holding: 180 [Q1] → 172 (-8) [Q2]
16% less capital invested
Capital invested by funds: $1.81B [Q1] → $1.51B (-$292M) [Q2]
29% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 5 (-2) [Q2]
32% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 22
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
Truist Securities
Asthika Goonewardene
|
$100
|
Buy
Initiated
|
10 Sep 2025 |
|
Stifel
Bradley Canino
|
$45
|
Buy
Reinstated
|
10 Sep 2025 |
|
Guggenheim
Brad Canino
|
$72
|
Buy
Initiated
|
4 Sep 2025 |
|
Piper Sandler
Kelsey Goodwin
|
$42
|
Overweight
Initiated
|
19 Aug 2025 |
|
Raymond James
Sean McCutcheon
|
$65
|
Outperform
Initiated
|
11 Jul 2025 |
Financial journalist opinion
